BioMarin Pharmaceuticals
BMRN
585 hedge funds and large institutions have $13.1B invested in BioMarin Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 99 funds opening new positions, 244 increasing their positions, 176 reducing their positions, and 55 closing their positions.
80% more first-time investments, than exits
New positions opened: 99 | Existing positions closed: 55
39% more repeat investments, than reductions
Existing positions increased: 244 | Existing positions reduced: 176
11% more call options, than puts
Call options by funds: $97.7M | Put options by funds: $87.7M
9% more capital invested
Capital invested by funds: $12B → $13.1B (+$1.05B)
8% more funds holding
Funds holding: 544 → 585 (+41)
1.62% more ownership
Funds ownership: 96.17% → 97.8% (+1.6%)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
+$110M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
+$108M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$81.2M |
| 4 |
Goldman Sachs
New York
|
+$72.9M |
| 5 |
Fuller & Thaler Asset Management
San Mateo,
California
|
+$56.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$258M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
-$96.1M |
| 3 |
Bank of New York Mellon
New York
|
-$68.7M |
| 4 |
VPC
Vestal Point Capital
New York
|
-$56.5M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$44.8M |
BMRN Hedge Fund Activity: Q1 2025 in Review
585 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q1 2025, worth a combined $13.1B — up 8.7% from $12B a quarter earlier.
Buyers outnumbered sellers: 99 funds opened new BMRN positions and 55 closed out — a net gain of 44 holders — while 244 added to existing stakes and 176 trimmed.
The largest buyer was AQR Capital Management, adding an estimated $110M. The largest seller was Capital Research Global Investors, cutting an estimated $258M.
- 585 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q1 2025, up from 544 in Q4 2024.
- Funds reported $13.1B of BioMarin Pharmaceuticals stock for Q1 2025, up 8.7% quarter-over-quarter.
- 99 funds opened new BioMarin Pharmaceuticals positions in Q1 2025 and 55 closed out, a net change of +44 holders.
- The largest BioMarin Pharmaceuticals buyer in Q1 2025 was AQR Capital Management, an estimated $110M added.
- The largest BioMarin Pharmaceuticals seller in Q1 2025 was Capital Research Global Investors, an estimated $258M sold.
Based on aggregated 13F filings for Q1 2025.